Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading its warrants under the ticker TDACW, is a blank-check company focused on the life sciences and healthcare sector. The company filed its annual report on Form 10-K with the SEC on March 31, 2025, indicating it remained active through at least the close of its most recent fiscal year. Consistent with its name, the vehicle targets opportunities in translational medicine and related biotech or pharmaceutical development verticals. The SPAC structure positions it to pursue a merger with an operating company in those fields. Visit SpacDesk and sign up for full data, filings, and deal-status tracking on Translational Development Acquisition Corp. and hundreds of other active SPACs.